Imprimis Pharmaceuticals Announces Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Imprimis Pharma (IMMY) Reports Q3 Loss of $0.29/Share
November 14, 2016 5:20 PM ESTImprimis Pharma (NASDAQ: IMMY) reported Q3 EPS of ($0.29), versus ($0.41) reported last year. Revenue for the quarter came in at $4.9 million, versus $2.7 million reported last year.
For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.
... More